Skip to content
Peptigraph home

CJC-1295 vs HGH: What the Research Shows

CJC-1295 and HGH side by side: what they are, how they are regulated and what is still unknown.

Medically reviewed by Juan Pablo Frías, MD · · DisclosureUpdated
GHRH analogNot FDA approved · research chemicalCJC-1295CJC-1295, a GHRH analog; in healthy adults a single injection produced dose-dependent rises in mean plasma GH of 2- to 10-fold and in IGF-I of 1.5- to 3-fold.[4]Growth hormoneRecombinant growth hormoneFDA approved (prescription only)HGHRecombinant human growth hormone, FDA-approved by prescription; in a randomized trial, 4 weeks of supraphysiological dosing did not improve power output or oxygen uptake.[14]Growth hormone
Quick verdict

Where the research points

Summary of studies, not a recommendation

Consider CJC-1295 if…

  • you want randomized human hormone data (hormone levels, not a clinical benefit): a single injection raised mean plasma GH 2- to 10-fold for 6 days or more[4]

Consider HGH if…

  • you want products with an FDA label: Genotropin (somatropin) is indicated for children with growth failure from inadequate growth hormone secretion[9]
  • you want randomized data in adults with growth hormone deficiency: Within 3 months lean body mass rose 5.09% and body fat fell 10.89%; waist fell 1.42%.[15]

What they have in common

  • WADA prohibits GHRH and its analogues at all times; its list names CJC-1295, sermorelin and tesamorelin[1]
  • Growth hormone is prohibited by WADA at all times, in and out of competition[1]
CJC-1295 is not FDA approved. Both are prohibited in tested sport (WADA). Status labels come from public FDA and WADA records; see the sources below.
Side by side

Spec comparison

Showing 8 of 11 fields where the two differ. Category, PCAC vote, Jul 2026, Evidence strength are the same or both unknown.

FieldCJC-1295HGH
ClassGHRH analogRecombinant growth hormone
Also calledCJC, mod GRF, GRF 1-29GH, growth hormone, generic HGH, IU
FDA statusNot FDA approved · research chemicalFDA approved (prescription only)
WADAProhibited by WADA (S2.2.4)CJC-1295 is named as a GHRH analogue in S2.2.4 (growth hormone releasing factors), prohibited at all times.Prohibited by WADA (S2.2.3)Growth hormone and its analogues and fragments are prohibited at all times (S2.2.3).
Anti-doping detection
  • A urine assay detects CJC-1295 and other GHRH analogues at very low concentrations.PMID 35298973
  • Labs expect GHRH analogues like CJC-1295 to be hard to find because of tiny urine concentrations; the study reports no detections in routine anti-doping samples.PMID 34665524
None reportedanti-doping literature, as of 2 Oct 2026
Half-lifeNo published half-life foundPubMed search, 11 Oct 20260.4 hours IV; 3.0 hours subcutaneousintravenous (normal adults); subcutaneous (GHD adults), Genotropin · FDA label (Genotropin)
Human studies we summarised4 human (1 randomized or controlled) of 7 summarised13 human (13 randomized or controlled) of 20 summarised
Typical study doses

Bracketed values are pending a sourced figure. Legal data reflects the regulatory events in our tracker.

A GHRH analogue that raises your own GH versus the hormone itself

The main CJC-1295 trial states that therapeutic use of GHRH to enhance GH secretion is limited by its short duration of action.[4]

In a proteomics follow-up, sera from 11 healthy young men before and after a CJC-1295 injection were analysed for protein changes. It is a biomarker study, not an outcome trial.[17]

For HGH, a 148-patient trial in adults with GH deficiency gave rhGH for 2 years, placebo-controlled for the first six months.[15]

The Genotropin label's weight-based adult dosing starts at not more than 0.04 mg/kg/week, with increases as tolerated at 4-8 week intervals.[9]

In a GH replacement trial, GH therapy impaired insulin-stimulated glucose uptake at 1 wk (-52%).[18]

Kinetics, label and sport status

After subcutaneous injection, Genotropin has a half-life of 3.0 hours on its label.[9]

In the CJC-1295 trial, the estimated half-life was 5.8-8.1 d.[4]

Common questions

CJC-1295 vs HGH: is CJC-1295 a substitute?

In the trial cited, CJC-1295 raised GH and IGF-I in healthy adults; the outcomes measured were hormone levels. HGH products are approved only for specific conditions.[4]

Which lasts longer in the body?

CJC-1295: its estimated half-life was 5.8-8.1 d, while the Genotropin label gives a half-life in hours.[4]

Sources

  1. 1World Anti-Doping Code International Standard Prohibited List 2026World Anti-Doping Agency · 2026wada-ama.orgAccessed 2 Oct 2026
  2. 2An antibody-free, ultrafiltration-based assay for the detection of growth hormone-releasing hormones in urine at low pg/mL concentrations using nanoLC-HRMS/MS.Journal of pharmaceutical and biomedical analysis · 2022PMID 35298973Accessed 2 Oct 2026
  3. 3Advances in the detection of growth hormone releasing hormone synthetic analogs.Drug testing and analysis · 2021PMID 34665524Accessed 2 Oct 2026
  4. 4Prolonged stimulation of growth hormone (GH) and insulin-like growth factor I secretion by CJC-1295, a long-acting analog of GH-releasing hormone, in healthy adults.The Journal of clinical endocrinology and metabolism · 2006PMID 16352683Accessed 2 Oct 2026
  5. 5Pulsatile secretion of growth hormone (GH) persists during continuous stimulation by CJC-1295, a long-acting GH-releasing hormone analog.The Journal of clinical endocrinology and metabolism · 2006PMID 17018654Accessed 2 Oct 2026
  6. 6Once-daily administration of CJC-1295, a long-acting growth hormone-releasing hormone (GHRH) analog, normalizes growth in the GHRH knockout mouse.American journal of physiology. Endocrinology and metabolism · 2006PMID 16822960Accessed 2 Oct 2026
  7. 7PubMed search: ("CJC-1295"[tiab] OR CJC1295[tiab]) (33 results)PubMed · 2026pubmed.ncbi.nlm.nih.govAccessed 2 Oct 2026
  8. 8PubMed search: ("CJC-1295"[tiab] OR CJC1295[tiab]) AND (half-life[tiab] OR pharmacokinetic*[tiab]) (7 results)PubMed · 2026pubmed.ncbi.nlm.nih.govAccessed 2 Oct 2026
  9. 9GENOTROPIN (SOMATROPIN) KIT [PFIZER LABORATORIES DIV PFIZER INC]FDA label (Genotropin), DailyMed · current labeldailymed.nlm.nih.govAccessed 2 Oct 2026
  10. 10Effect of growth hormone on aging connective tissue in muscle and tendon: gene expression, morphology, and function following immobilization and rehabilitation.Journal of applied physiology (Bethesda, Md. : 1985) · 2014PMID 24235105Accessed 2 Oct 2026
  11. 11Impact of GH replacement therapy on sleep in adult patients with GH deficiency of pituitary origin.European journal of endocrinology · 2013PMID 23447518Accessed 2 Oct 2026
  12. 12Local administration of growth hormone stimulates tendon collagen synthesis in elderly men.Journal of applied physiology (Bethesda, Md. : 1985) · 2012PMID 22961272Accessed 2 Oct 2026
  13. 13PubMed search: ("CJC-1295"[tiab] OR CJC1295[tiab]) AND (somatropin[tiab] OR "recombinant human growth hormone"[tiab] OR "recombinant growth hormone"[tiab] OR rhGH[tiab] OR "growth hormone therapy"[tiab] OR "growth hormone treatment"[tiab] OR "growth hormone replacement"[tiab] OR "growth hormone administration"[tiab] OR "GH therapy"[tiab] OR "GH treatment"[tiab] OR "GH replacement"[tiab] OR "GH administration"[tiab] OR "growth hormone injection"[tiab] OR "growth hormone injections"[tiab] OR "growth hormone supplementation"[tiab])PubMed · 2026pubmed.ncbi.nlm.nih.govAccessed 2 Oct 2026
  14. 14Short-term administration of supraphysiological recombinant human growth hormone (GH) does not increase maximum endurance exercise capacity in healthy, active young men and women with normal GH-insulin-like growth factor I axes.The Journal of clinical endocrinology and metabolism · 2005PMID 15784718Accessed 2 Oct 2026
  15. 15Two years of replacement therapy in adults with growth hormone deficiency.Clinical endocrinology · 1997PMID 9404448Accessed 2 Oct 2026
  16. 16PubMed search: ("CJC-1295"[tiab] OR CJC1295[tiab]) AND (adverse[tiab] OR "side effect*"[tiab] OR safety[tiab] OR tolerab*[tiab] OR toxicity[tiab] OR "case report"[pt]) (11 results)PubMed · 2026pubmed.ncbi.nlm.nih.govAccessed 11 Oct 2026
  17. 17Activation of the GH/IGF-1 axis by CJC-1295, a long-acting GHRH analog, results in serum protein profile changes in normal adult subjects.Growth hormone & IGF research : official journal of the Growth Hormone Research Society and the International IGF Research Society · 2009PMID 19386527Accessed 2 Oct 2026
  18. 18Growth hormone replacement therapy induces insulin resistance by activating the glucose-fatty acid cycle.The Journal of clinical endocrinology and metabolism · 2003PMID 12679422Accessed 2 Oct 2026

Found an error? Report a correction.